Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)
Clinical trial NCT06052436 · RECRUITING
Trial details
- NCT number
- NCT06052436
- Sponsor
- Hospital General Universitario Gregorio Marañon
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-27
- Primary completion
- 2027-12-31
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.